arrow
C

Chiara Cremolini

University Hospital of Pisa
H指数:65
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial

新辅助botensilimab联合或不联合balstilimab治疗pMMR和dMMR结肠癌: UNICORN 2期试验

2026-11-020
OAAI
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms

转移性结直肠癌随机试验中基于ARCAD衍生外部对照臂的总体生存期可重复性

2026-08-220
PRE
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

通过血浆谱分析确定的癌症免疫治疗结果的代谢决定因素

2026-06-250
OAAI
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study

可切除性错配修复 proficient 结直肠癌的放射学分期一致性:一项观察者间一致性研究

2026-06-010
PRE
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years

极早期转移性结直肠癌的分子和临床侵袭性差异:30-39岁与40-49岁患者间的生存和基因组分歧

2026-06-010
OAAI
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

微卫星稳定型转移性结直肠癌对化疗免疫联合治疗的反应的空间预测因子

2026-04-250
OAAI
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Tucatinib联合曲妥珠单抗治疗化疗难治性、HER2阳性、RAS野生型转移性结直肠癌(MOUNTAINEER):最终分析

2026-01-120
OAAI
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings

基于衰减的心肌细胞外体积估计:从非门控心电图全身CT检查作为化疗诱导的心脏毒性早期生物标志物的初步发现

2025-11-180
PRE
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: an ARCAD database study

随着奥沙利铂为基础的化疗联合靶向药物,转移性结直肠癌的生存率随时间推移呈逐年改善:一项ARCAD数据库研究

2025-10-020
OAAI
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients

早发性结直肠癌患者表现出独特的分子特征:来自一项包含1209例患者的全基因组测序研究的见解

2025-09-010
OAAI
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

原发肿瘤侧别及负超选择对RAS野生型转移性结直肠癌患者抗EGFR为基础维持疗法的影响:两项随机临床试验的个体患者数据合并分析

2025-08-280
OAAI
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: an individual patient data-based pooled analysis of randomized trials

FOLFOXIRI/bevacizumab与双药/bevacizumab作为不可切除的肝-only、右侧和/或RAS或BRAF突变转移性结直肠癌初始治疗的比较:一项基于个体患者数据的随机试验合并分析

2025-08-150
PRE
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

KRASG12C突变化疗难治性转移性结直肠癌患者接受Sotorasib联合帕尼单抗或标准治疗(CodeBreaK 300):一项III期随机临床试验的结果

2025-08-110
OAAI
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial

FOLFIRINOX或FOLFOX用于局部晚期或转移性小肠腺癌:PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA II期随机试验

2025-07-280
OAAI
Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO

fruquintinib 在较少预治疗患者中的研究:FRESCO-2 与 FRESCO 的多变量配型匹配分析

2025-07-130
OA
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors

MSI-High结直肠癌患者接受免疫检查点抑制剂治疗后BRAF V600E突变对预后的影响

2025-07-120
PRE
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study

整合组织与液体活检综合基因组分析以预测抗EGFR疗法在转移性结直肠癌中的疗效:CAPRI-2 GOIM研究的结果

2025-07-120
PRE